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Abstract 
These updated guidelines from the Infectious Diseases Community of Practice of the 
American Society of Transplantation review the diagnosis, prevention and management of 
HHV-6A, HHV-6B, HHV-7, and HHV-8 in the pre- and post-transplant period. The majority 
of HHV-6 (A and B) and HHV-7 infections in transplant recipients are asymptomatic; 
symptomatic disease is reported infrequently across organs. Routine screening for HHV-6 
and 7 DNAemia is not recommended in asymptomatic patients, nor are prophylaxis or 
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preemptive therapy. Detection of viral nucleic acid by quantitative PCR in blood or CSF is 
the preferred method for diagnosis of HHV-6 and HHV-7 infection. The possibility of 
chromosomally-integrated HHV-6 DNA should be considered in individuals with persistently 
high viral loads. Antiviral therapy should be initiated for HHV-6 encephalitis and should be 
considered for other manifestations of disease.  HHV-8 causes Kaposi’s sarcoma, primary 
effusion lymphoma, and multicentric Castleman disease and is also associated with 
hemophagocytic syndrome and bone marrow failure. HHV-8 screening and monitoring may 
be indicated to prevent disease.  Treatment of HHV-8 related disease centers on reduction of 
immunosuppression and conversion to sirolimus, while chemotherapy may be needed for 
unresponsive disease. The role of antiviral therapy for HHV-8 infection has not yet been 
defined. 
 
Human Herpesviruses 6 and 7 
Etiology and description of the pathogens 
Human herpesvirus 6A (HHV-6A), HHV-6B, and HHV-7 are three closely related species 
within the subfamily Betaherpesvirinae. Like other herpesviruses, all three species establish 
lifelong latent infection in the host following primary infection and may then reactivate and 
undergo lytic replication in the setting of immunosuppression. HHV-6A and HHV-6B share 
approximately 90% amino acid identity but are two distinct species and utilize different host 
cell receptors (CD46 for HHV-6A and CD134 for HHV-6B) (1-3). Although some studies 
have suggested that HHV-6A exhibits relative neurotropism (4), little is known of how 
clinical presentation may differ between HHV-6A and HHV-6B, particularly in solid organ 
transplant (SOT) recipients. Epidemiological factors that differentiate HHV-6A from HHV-
6B will be discussed below. However, the two viruses will be referred to under the collective 
name of HHV-6 when discussing studies in which the viruses were not analyzed separately or 
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in areas where differentiation between the two viruses is not known to impact clinical 
management. 
 
HHV-6A and HHV-6B are unique in their ability to covalently integrate into the subtelomeric 
region of human chromosomes, resulting in chromosomally-integrated HHV-6 (CIHHV-6) in 
germ cells (5, 6). When this occurs, HHV-6 DNA is then transmitted to offspring in a 
Mendelian manner via germ cell lines. Individuals with CIHHV-6 have at least one copy of 
HHV-6 DNA in every cell and therefore have exceedingly and persistently high levels of 
detectable HHV-6 DNA in blood and tissue samples, which may complicate interpretation of 
diagnostic studies (7). CIHHV-6 is estimated to occur in approximately 1% of the general 
population in the U.S. and Europe, with 2/3 of cases secondary to HHV-6B (8). The impact 
of CIHHV-6 on transplant remains an important area of study that is further discussed below.  
 
Epidemiology and risk factors 
HHV-6A, HHV-6B, and HHV-7 are presumed to be transmitted within the general 
population via contact with infected saliva (9-12). By adulthood, nearly 90% of individuals 
are seropositive for both HHV-6 and HHV-7 (12-16). Thus most infections after transplant 
are thought to result from the reactivation of latent virus; donor-derived transmission of 
HHV-6, including CIHHV-6, has been reported via hematopoietic stem cell transplant and 
SOT (17-23).  
 
The estimated prevalence of HHV-6 reactivation among SOT recipients varies widely from 
20-82% (17, 24-27), due in part to the variability of diagnostic assays and the inability of 
some tests to distinguish active from latent infection. The majority of reactivation events in 
SOT recipients are secondary to HHV-6B (24, 25, 27, 28), although not all prevalence studies 
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utilized diagnostic assays that discriminated between HHV-6A and HHV-6B (17, 29, 30). 
There is less information on the rate of active HHV-7 infection after SOT, with reported rates 
of reactivation varying widely between 0-46% of recipients (24, 31-33). Reactivation of both 
HHV-6 and HHV-7 has been reported to first occur most frequently within the first 2-4 
weeks SOT (17, 24, 25, 27-29, 34, 35).  
 
Clinical manifestations  
The majority of HHV-6 and HHV-7 reactivation events in both pediatric and adult SOT 
recipients are asymptomatic (28-30, 35). In the context of presumed symptomatic infection, a 
wide range of clinical signs and symptoms have been attributed to HHV-6 in SOT recipients, 
including fever, rash, bone marrow suppression, hepatitis, gastroduodenitis, colitis, and 
pneumonitis (28, 30, 31, 34-42), with fever and bone marrow suppression reported most 
commonly (43). Limbic encephalitis secondary to HHV-6 is a well-described entity in the 
stem cell transplant population (44) but seems to be less common in the SOT population (35, 
45, 46). CIHHV-6 does have the potential to reactivate and result in symptomatic disease (6, 
47-50). However the limited data available from SOT populations suggest that clinically 
apparent disease secondary to CIHHV6 is uncommon in these patients (51, 52). Clinically-
apparent HHV-7 disease seems to be infrequent among SOT recipients and has been reported 
to result in non-specific febrile syndrome with thrombocytopenia and bone marrow 
suppression (53-55).  
 
Pediatric patients who undergo transplant during the first few years of life are theoretically 
more likely to acquire primary HHV-6 or HHV-7 infection post transplant. 24% of children 
were diagnosed with primary HHV-6 infection in one study of 80 young pediatric heart, 
kidney, and liver recipients; only three children in the entire study cohort were presumed to 
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be HHV-6 uninfected by the end of the study period (35). Although mean peak HHV-6 viral 
load (utilizing quantitative polymerase chain reaction [PCR] that did not differentiate HHV-
6A from HHV-6B) was significantly higher among children with primary infection, children 
with primary infection were no more likely to have symptoms attributable to HHV-6 
compared to children with reactivation. The duration of HHV-6 DNAemia did not differ 
significantly between children with primary infection compared to those wtih viral 
reactivation (35). Signs and symptoms attributed to primary or reactivated HHV-6 infection 
in this study included fever, diarrhea, rash, seizures, lymphopenia, and elevated alanine 
aminotransferase level. A study of HHV-6 DNAemia among pediatric liver transplant 
recipients reported symptoms attributable to HHV-6 to be infrequent and included vomiting, 
lethargy, splenomegaly, and bone marrow suppression (30). Limited data from pediatric liver 
transplant recipients suggest that both HHV-7 DNAemia and symptomatic HHV-7 disease, 
either secondary to primary infection or reactivation, is uncommon among transplanted 
children (33). 
 
Several studies have attempted to investigate immunomodulatory properties of HHV-6 and 
HHV-7 that may potentiate risk of opportunistic infection and allograft rejection. 
Epidemiological associations have been reported between HHV-6 and fungal infections (56-
58), early fibrosis due to hepatitis C virus recurrence after liver transplant (59, 60), and 
greater risk of mortality rate after liver (57, 61) and heart-lung transplant (58). Both HHV-6 
and HHV-7 have been detected in bronchoalveolar lavage fluid, although it is not clear if 
viral detection contributes to bronchiolitis obliterans syndrome after lung transplant (62, 63). 
HHV-6 and HHV-7 infections have also been associated with allograft rejection and 
dysfunction (26, 64, 65), but the presence of CMV may confound the reported associations.   
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Studies have suggested an association between HHV-6 and HHV-7 reactivation and 
increased risk of CMV disease among adult kidney and liver recipients (31, 32, 64, 66-69), 
but it is unclear if HHV-6 and 7 infection truly potentiates CMV disease or if the presence of 
these viruses instead represents more intensive immunosuppression and its attendant risk of 
CMV. Among a subset of adult SOT recipients with CMV disease who received CMV-
directed antiviral therapy as part of a multicenter, prospective clinical trial, HHV-6 and 
HHV-7 infections were detected among nearly 17% of subjects (70). HHV-6 and HHV-7 
infections were not associated with time to CMV disease resolution or risk of CMV 
recurrence and in general did not seem to impact the clinical course of CMV disease. These 
results suggest that evaluation for HHV-6 or HHV-7 infection in the setting of CMV disease 
is not routinely indicated, and detection of co-infection is unlikely to impact CMV clinical 
course or management. HHV-6 DNAemia was not associated with increased risk of 
subsequent CMV DNAemia in pediatric liver transplant recipients (28, 30) and was not 
associated with increased risk of CMV DNAemia or graft rejection in a cohort of pediatric 
heart, kidney, and liver transplant recipients (35).  
 
Limited data suggest that CIHHV-6 may exert indirect effects post transplant. Liver 
transplant recipients who were known to have CIHHV6 prior to transplant were subsequently 
at greater risk for bacterial infection when compared to a cohort without CIHHV6 but were 
not at significantly greater risk for other opportunistic infections graft rejection (52).  
 
Diagnostic strategies 
Diagnostic tests for HHV-6 and HHV-7 include serology, culture, histopathology with 
immunohistochemistry, antigenemia, and nucleic acid amplification tests (typically PCR). 
Given the ubiquitous nature of infection and the limitations of serological assays in 
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immunocompromised hosts, serology is minimally informative in SOT recipients (24, 55, 
71). Viral isolation in cell culture is highly specific for active infection (72, 73) but is not 
widely available through most laboratories and thus is not routinely recommended.  
 
For suspected HHV-6 disease, tissue biopsy may be performed where possible to confirm the 
diagnosis or rule out other etiologies. Immunohistochemistry to detect viral antigens in 
biopsy specimens (26, 37, 74) is of minimal clinical utility as it is not widely available, and 
HHV6 antigens may be detected in tissue in the absence of symptoms (75, 76).  
 
Antigenemia assays have largely been supplanted by quantitative PCR (71, 72), which is the 
preferred assay for the detection of HHV-6 and HHV-7 DNAemia and presumed active 
infection after SOT.  Quantitative PCR may be helpful in diagnosing active infection and in 
monitoring response to intervention. PCR can be used to quantify HHV-6 and HHV-7 DNA 
from peripheral blood mononuclear cells (PBMC), plasma, serum, and whole blood. PCR 
may also be used to detect HHV-6 and HHV-7 DNA from tissue, bronchoalveolar lavage 
fluid, and cerebrospinal fluid. Many clinical and translational studies have utilized PCR for 
the U38 gene common to both HHV-6A and HHV-6B to diagnose HHV-6 DNAemia without 
differentiating between the two variants (29, 30, 35, 72), but variant-specific PCR is available 
as well (73, 77, 78). Quantitative PCR is preferred over qualitative for both HHV-6 and 
HHV-7, as a single test result with a low viral load may indicate a false positive result (72), 
and very high, sustained HHV-6 viral loads may suggest CIHHV6 (8). Quantitative PCR 
from plasma or serum is widely available and is preferred over whole blood or PBMC for 
diagnosis of active infection; these fluids are relatively cell-free but may still contain viral 
DNA from lysed cells (79). Quantitative HHV-6 DNA PCR from plasma is reported to be 
approximately 84% specific for actively replicating virus (72).  
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It is important to note that PCR assays available for both HHV-6 and HHV-7 are limited by a 
lack of standardization and validation. A study using serum samples spiked with known 
concentrations of HHV-6A DNA found significant variability of viral loads among different 
PCR assays (80). Data are also insufficient to determine the level of detectable HHV-6 or 
HHV-7 DNA in a biological sample that should be considered clinically significant in SOT 
recipients.  
 
Interpretation of PCR assays is also complicated by the fact that detection of HHV-6 or 
HHV-7 DNA does not confirm causality in a given clinical syndrome (81) and may occur 
even in otherwise immunocompetent patients in the setting of sepsis or other severe disease 
(82). HHV-6 DNA has been detected in CSF from both immunocompromised and 
immunocompetent patients in the absence of neurological dysfunction (83, 84), thus the 
diagnosis of HHV-6 encephalitis should be considered in the context of both clinically-
compatible symptoms and detection of HHV-6 DNA in CSF. Characteristic changes observed 
by magnetic resonance imaging (MRI) may also support the diagnosis (85). Although at least 
one study as reported higher HHV-6 CSF viral loads among SCT recipients with HHV-6 
encephalitis, the threshold CSF viral load that best correlates with diagnosis is unknown (84). 
In general, diagnostic testing for HHV-6 or HHV-7 should be limited to scenarios where 
symptomatic infection is plausible, and to assist in guiding treatment decisions. The diagnosis 
of symptoms directly related to HHV-6 or HHV-7 requires the careful exclusion of other 
etiologies.  
 
The infrequent but well-described phenomenon of CIHHV6 should also be considered when 
interpreting HHV-6 viral loads. Recognition of CIHHV is important in order to avoid 
unnecessary antiviral therapy among individuals who have persistently elevated HHV6 viral 
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loads but no clearly attributable symptoms (51). CIHHV6 is suggested by extremely and 
persistently elevated HHV-6 viral loads that show minimal fluctuation when followed over 
time (8). Although persistent elevation of plasma or serum viral load may suggest the 
possibility of CIHHV, the diagnosis is more certain when the viral load is assayed in whole 
blood or isolated PBMC (8). Because individuals with CIHHV have at least one HHV-6 
genomic copy per white blood cell, these individuals typically have HHV6 viral loads in 
whole blood or PBMC of at least 5.5 log10 copies/ml (7, 8, 86, 87).  Testing of hair follicles or 
nails or use of fluorescence in situ hybridization (FISH) have been used to confirm CIHHV 
(87, 88) but are labor intensive and typically not necessary for establishing the diagnosis (8). 
Thus individuals with CIHHV may be identified by persistent elevation of viral load from 
whole blood or PBMC (8) or through use of droplet digital PCR (89-91), with testing of 
family members or other more specific diagnostic modalities as needed. 
 
Treatment 
The majority of HHV-6 and HHV-7 infections are subclinical and transient, thus treatment of 
asymptomatic DNAemia is not recommended. Treatment directed against HHV-6 should be 
initiated in the setting of HHV-6 encephalitis. Treatment should be considered for other 
clinical syndromes attributable to HHV-6 and HHV-7. Especially in cases of moderate or 
severe disease attributed to HHV-6 or HHV-7, antiviral treatment may be complemented by 
reduction in pharmacologic immunosuppression. 
 
It should be noted that there are no antiviral compounds licensed for HHV-6 or HHV-7 
infections, and there are no randomized, controlled trials demonstrating antiviral efficacy for 
the treatment of HHV-6 or HHV-7-related disease in SOT recipients. Recommendations for 
use of antivirals in the setting of HHV-6 and HHV-7 are based on in vitro data and limited 
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clinical reports. In vitro data suggest similar antiviral susceptibility patterns for HHV-6A and 
HHV-6B (92). Ganciclovir, foscarnet, cidofovir, and brincidofovir all inhibit HHV-6 
replication in vitro at clinically-achievable concentrations (91, 93, 94); cidofovir and 
foscarnet seem to exhibit more potent activity in vitro (91). HHV-6 appears resistant to 
acyclovir (93). Ganciclovir resistance may occur through mutations of the U69 and U28 
HHV-6 genes (95, 96), and a mutation of the HHV-6 U38 gene resulting in cidofovir 
resistance has also been reported (97). Ganciclovir, foscarnet, and cidofovir have all been 
utilized in SOT recipients in the setting of HHV-6 infection (22, 28, 98-100) and may be used 
for treatment of HHV-6 disease. Use of both ganciclovir and foscarnet has been associated 
with reduction of HHV-6 viral load in both serum and cerebrospinal fluid in SCT recipients 
with HHV-6 encephalitis, although response to antivirals was not universal in this study (44). 
Valganciclovir has been used in adult liver transplant recipients with HHV-6 DNAemia (29), 
but data are insufficient to support its use in severe disease such as encephalitis.  
 
Cidofovir and foscarnet inhibit HHV-7 replication in vitro (91). HHV-7 appears resistant to 
ganciclovir and acyclovir in vitro and does not seem to be inhibited by clinically achievable 
concentrations of ganciclovir (93, 101). Foscarnet and cidofovir have been used for treatment 
of HHV-7 infection in SOT recipients and may be used for treatment of HHV-7 disease.  
 
Adoptive immunotherapy for severe HHV-6 disease with cytotoxic T-lymphocytes has been 
used in an investigational setting, primarily among the stem cell transplant and primary 
immune deficiency populations (102, 103).  
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Prevention: prophylaxis and pre-emptive therapy 
Specific antiviral prophylaxis or pre-emptive therapy directed against HHV-6 and HHV-7 is 
not recommended, nor is routine monitoring for HHV-6 and HHV-7 DNAemia post 
transplant, as the vast majority of infections after SOT are subclinical, even among pediatric 
patients who are suspected to have primary infection (28-30, 35). Although some studies 
have suggested a decreased risk of HHV-6 infection in the setting of CMV prophylaxis (54, 
104), other studies in both adult and pediatric SOT recipients found that both HHV-6 and 
HHV-7 DNAemia occur frequently with doses of ganciclovir and valganciclovir typically 
used for both CMV prophylaxis and treatment (29, 35, 54, 70, 101).  
 
Research and future areas of investigation 
Large, prospective, and ideally multicenter studies are needed to accurately quantify the 
burden of disease that is truly attributable to HHV-6 (including CIHHV-6) and HHV-7 in 
SOT recipients and to elucidate the underlying host-viral mechanisms that may contribute to 
indirect effects on patient outcomes and graft function. These studies could also provide 
further evidence to support or disprove the need for preemptive monitoring after transplant. 
Randomized, controlled trials are needed to assess the efficacy of various antivirals and to 
evaluate the safety and efficacy of immunomodulatory therapies, including adoptive 
immunotherapy.  
 
HHV-6 and HHV-7 recommendations and level of evidence 
Diagnosis 
Serological studies for HHV-6 and HHV-7 are not recommended in the evaluation of SOT 
candidates or recipients (strong, low).  
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Culture, while highly specific for active infection, is not widely available and is not routinely 
recommended (strong, low).  
 
For suspected HHV-6 disease, tissue biopsy may be performed where possible to confirm the 
diagnosis or rule out other etiologies (weak, low). 
 
Detection of viral nucleic acid by quantitative PCR in blood or CSF is the preferred method 
for diagnosis of HHV-6 and HHV-7 infection and is recommended over antigenemia assays 
(strong, moderate).  
 
Viral nucleic acid may also be detected from bronchoalveolar lavage fluid and tissue by PCR 
and may be informative performed in the appropriate clinical context (weak, low).  
 
Diagnostic testing for HHV-6 or HHV-7 should be limited to scenarios where symptomatic 
infection is plausible, as detection of viral nucleic acid or antigen may be insufficient 
evidence of disease in the absence of clinically compatible symptoms (strong, moderate).  
 
CIHHV6 should be a consideration in individuals with persistent, high grade DNAemia and 
may be diagnosed by serial monitoring of viral load by PCR of whole blood or PBMC or by 
droplet digital PCR (strong, low). 
 
Treatment  
The majority of HHV-6 and HHV-7 infections are asymptomatic, transient, and do not 
require antiviral treatment (strong, moderate). 
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Antiviral treatment with foscarnet, ganciclovir, or cidofovir should be initiated in the setting 
of HHV-6 encephalitis (strong, moderate).  
 
Treatment should be considered for other syndromes attributable to HHV-6 or HHV-7 (weak, 
low).  
 
Especially in cases of moderate or severe disease, antiviral treatment may be complemented 
by reduction of immunosuppression (strong, low).  
 
Prevention  
Antiviral prophylaxis and preemptive antiviral therapy for HHV-6 or HHV-7 infections are 
not recommended after transplant (strong, low).  
 
Routine monitoring for HHV-6 and HHV-7 infections after SOT is not recommended 
(strong, low).  
 
HHV-8  
Etiology and description of the pathogen 
Human herpesvirus 8 (HHV-8), or Kaposi’s sarcoma herpesvirus (KSHV), gained increased 
attention in the height of the acquired immune deficiency syndrome (AIDS) epidemic as 
Chang et al first discovered it as the etiologic agent of Kaposi’s sarcoma (KS) in 1994(105).  
Four variants have been described:  classic, endemic, iatrogenic or immunosuppression-
associated, and epidemic or AIDS-associated(106).  Soon after, HHV-8 was found to be the 
causative agent of primary effusion lymphoma (PEL) and forms of multicentric Castleman 
disease (MCD)(107, 108).  HHV-8 has also been associated with severe, non-neoplastic 
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complications such as hemophagocytic syndrome, pancytopenia, hepatitis and KS-associated 
herpesvirus inflammatory cytokine syndrome in SOT recipients(109, 110). 
 
HHV-8, a DNA gammaherpesvirus, exhibits both latent and lytic phases.  Primarily infecting 
B-cells, macrophages, endothelial (“spindle cells” in KS lesions) and epithelial cells, the 
virus can establish lifelong latency after acute infection.  The viral and host complexities 
influencing lytic replication, ultimately resulting in production of infectious virions, have not 
been fully elucidated.  However, lytic activation by inflammatory cytokines, coinfecting 
viruses, oxidative stress and tissue hypoxia have been described(111),(112).  Host immunity, 
mediated through CD4+ and CD8+ T-cell responses, plays a critical role in controlling HHV-
8 replication and is necessary for post-transplant KS (PT-KS) regression, (113), (114). 
Clinically, the role of this cellular mediated immune control of HHV-8 has been supported by 
observed regression of KS after immune-reconstitution with antiretroviral therapy in AIDS 
patients and after reduction of T-cell specific immunosuppression in SOT recipients(106, 
114-116).  The virus encodes for specific gene products such as latency associated nuclear 
antigen 1 (LANA-1), a viral analogue of human interleukin-6 (vIL-6), and microRNAs which 
help the virus evade host innate and adaptive immune responses.  Eventually this interferes 
with cell cycle and apoptosis control creating an inflammatory milieu supporting tumor 
growth and angiogenesis(117).  Though latently-infected cells contribute to a majority of 
HHV-8 associated cancers, lytic replication is also suspected to promote tumorigenesis and is 
indirectly supported by observed decreased risk of KS development among patients receiving 
antiviral therapy(118-121).  Transmission of virus occurs primarily through saliva but may be 
transmitted sexually through semen and cervicovaginal secretions, vertically through breast 
milk, by intravenous drug use or blood transfusion, and through transplant (122-124). 
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Epidemiology and risk factors 
Rates of HHV-8 infection and seropositivity demonstrate significant geographic diversity as 
well as subgroup and transmission pattern heterogeneity.  Furthermore, lack of a standard 
serological test obfuscates true seroprevalence estimates.  In the United States (US) an 
estimated 3-7% of blood donors are seropositive but with minimal rates of HHV-8 DNA 
detected(125).  Similarly low seroprevalence has been reported in northern European, 
southeast Asian, and Caribbean countries(126).  Higher rates of HHV-8 seropositivity are 
found in the Middle East, Mediterranean (5-20%) and sub-Saharan Africa (>50%)(127, 128).  
Globally, the pooled seroprevalence among men who have sex with men (MSM) has recently 
been estimated to be 33% and over 40% among MSM who are infected with human 
immunodeficiency virus (HIV) (129). 
 
Unsurprisingly, rates of KS mirror global HHV-8 seroprevalence. The incidence of KS 
among the general population is low(130). World-wide, the incidence of PT-KS appears to 
have risen in the modern era though a recent registry study suggests an overall decrease in 
incidence in the US specifically(130, 131). In endemic regions, PT-KS comprises 35-87.5% 
of all post-transplant neoplasms but accounts for less than 10-15% in parts of Europe and the 
US(132-134).  Cumulative incidence of PT-KS ranges from 0.3-0.8% in non-endemic regions 
to 3.2-5.3% in endemic regions(132-138).  Geographic areas within countries with diverse 
subpopulations and varied donor and recipient HHV-8 seroprevalence, such as Italy and 
Spain, may demonstrate different transplant center-specific PT-KS rates(136, 137, 139). 
Further, as the US foreign-born population grows, donors and recipients from HHV-8 
endemic areas may become more common.     The reported incidence per 100,000 person 
years is highest in kidney recipients than liver or heart recipients with cases in lung transplant 
recipients being least common (130).   
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Post-transplant HHV-8 seroconversion in endemic areas may be seen in 14-33% of 
patients, with DNAemia detected in a minority of patients(140, 141).  Similarly, a recent 
study from north central Italy prospectively screening donors and recipients found that 4% 
of donors and 18% of recipients were HHV-8 seropositive, and 25% of serologically 
mismatched recipients seroconverted within 6 months. Reactivated HHV-8 post-transplant 
was seen in 2.1%, and one individual developed PT-KS(136).  Though donor transmission 
has been well described, and serologic mismatch is a known risk for primary recipient 
disease, HHV-8 DNAemia in the post-transplant setting is most commonly from 
reactivated virus(136, 142-144). Among liver allograft recipients, donor transmission 
events are more frequent and may present earlier with more aggressive disease when 
compared to recipients of other organs. (124, 137, 140, 144, 145).  This may relate to the 
liver’s size and vascularity or suggest the presence of a larger hepatic reservoir of infected 
cells. 
 
The risk of KS in the SOT population is also low but is still at least 200 to 500-fold greater 
than that observed in the general population (146-148).  Though HHV-8 seropositivity is 
the key risk factor for PT-KS, other factors include HLA-B mismatching, African or 
Middle Eastern origin, lung transplant, older age at transplant and receipt of 
antilymphocyte agents(113, 114, 131, 143, 146, 149). As more HIV positive recipients are 
being transplanted worldwide, and as HIV positive donor organs are being recovered more 
frequently in the setting of the HIV Organ Policy Equity (HOPE) Act, the epidemiology of 
HHV-8 related diseases may evolve and further risk factors may be identified.  Recent case 
reports of PT-KS and other HHV-8 related diseases in HIV positive transplant recipients 
have been described(150, 151). The ongoing opioid epidemic in the United States has 
contributed to an increase in donors classified as Public Health Service (PHS) increased 
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risk (152).   Though donors defined as PHS increased risk, particularly those who inject 
drugs, may have an increased risk of HHV-8 infection, the actual prevalence and 
subsequent transmission risk amongst this donor group is unknown. 
 
KS after a kidney transplant does not automatically preclude re-transplant. A recent 
retrospective review from France found a 25% (2/8) KS recurrence rate after a second 
kidney transplant in those patients who had PT-KS after their first transplant.  This was 
similar to the rate of primary KS among first-time transplants, and disease resolved in both 
recipients with tapering of immunosuppressive medications.  A longer delay from KS 
remission to second transplant may be associated with a lower recurrence risk(153). 
 
Clinical manifestations 
 
Patients infected with HHV-8 can present with both neoplastic and non-neoplastic 
manifestations concomitantly, and associated DNAemia may be infrequent(113, 114, 141, 
154, 155).  The severity, timing and type of HHV-8 related disease may differ by organ 
transplanted, with thoracic and liver transplant recipients more commonly presenting with 
more severe signs and symptoms(140, 156).  Patients may present with mild signs and 
symptoms of fever, maculopapular rash, lymphadenopathy, and cytopenias(157). However, 
HHV-8 associated lymphoproliferative B-cell disorders, clonal gammopathies, hepatitis, fatal 
bone marrow failure, and hemophagocytic syndromes have been reported(144, 154, 155, 158-
161). Recently Mularoni et al. described a case of KS-associated inflammatory cytokine 
syndrome (KICS) in a liver-kidney transplant recipient(109).  Proposed clinical criteria for 
this syndrome, which is recognized in HIV positive patients, include a constellation of 
clinical symptoms, radiographic and histologic abnormalities, cytokine profiles, 
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inflammatory biomarkers and other laboratory abnormalities and can result in fatal organ 
damage(109).   
 
PT-KS is the most commonly reported HHV-8 related disease and neoplastic manifestation 
after SOT.  On average, PT-KS presents within 13 months (3 – 16 months) after transplant 
and peaks within one year but may present many years after transplant(131, 146, 148). Onset 
also varies by organ transplanted, with earlier presentation seen after liver transplant when 
compared to kidney transplant(137).   A majority of PT-KS lesions involve skin of the 
extremities and trunk and mucosal surfaces of gingiva, and hard and soft palates and has been 
associated with cutaneous squamous cell carcinoma(131, 132, 162).  Visceral involvement 
occurs in 10% of PT-KS, with 50% occurring in liver transplant recipients which may 
directly involve the allograft(163).  Mortality rates up to 60% have been described(164).   
 
MCD is characterized by B-cell transformation to plasmablasts, which subsequently infiltrate 
multiple lymph nodes and distort their architecture.  It can be seen after primary HHV-8 
infection or reactivation and typically presents with fevers, lymphadenopathy, hepato-
splenomegaly, and cytopenias. MCD is commonly associated with increased IL-6 and IL-10 
production(165, 166).  Less commonly, primary effusion lymphoma, an HHV-8 driven, non-
Hodgkin, body cavity lymphoma, has been reported after SOT.  PEL can involve the serosal 
surfaces of the pleura, pericardium and peritoneum and carries a significant 1-year 
mortality(167).  
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Diagnostic Strategies 
Historically, serologic testing with indirect immunofluorescence assays (IFA), enzyme-linked 
immunosorbent assays (ELISA) and Western blot assays targeting both HHV-8 latent and 
lytic viral antigens have variable sensitivity and specificity ranging from 60-100%, with 
poorer performance seen in lower seroprevalence populations(168, 169).  In a recent 
multicenter, prospective evaluation of six HHV-8 serological assays (four IFAs and two 
ELISAs), only two of six lytic antigen-based IFAs demonstrated agreement with the 
predefined reference standard(136).  Given the lack of standardization, as well as variable 
sensitivity and specificity, serological assays are of limited utility for the diagnosis of HHV-8 
related disease .  
 
Globally, HHV-8 serologic testing is not routinely included in pre-transplant screening, with 
low rates of donor and recipient screening reported (27.3% and 11.4% respectively) even in 
endemic areas(170).  In endemic areas, universal donor and recipient screening may be useful 
to assess the risk of post-transplant HHV-8 disease but is not recommended in regions with 
low seroprevalence. Targeted screening of at-risk donors and recipients or those from 
endemic regions may be considered in low seroprevalence areas though seropositivity is not a 
routine contraindication to transplant. All pre-transplant HHV-8 serologic tests should be 
cautiously interpreted as performance may vary widely depending on assay characteristics 
and antigen preparations (136, 168).   
 
When HHV-8 syndromes are suspected, biopsy tissue of involved sites (e.g. tumor tissue for 
KS, lymph node for MCD, pleural or ascitic fluid for PEL) should be obtained for 
histopathology with HHV-8 immunohistochemical staining and in situ hybridization or viral 
PCR testing to aide in diagnosis(171). Characteristic spindle-shaped cells along with latency 
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associated nuclear antigen (LANA) and CD34 positive staining are common features of PT-
KS lesions(172, 173).   
 
Quantitative PCR from clinical samples may be useful for the diagnosis of HHV-8 related 
disease and is the preferred method to detect actively replicating virus(171). HHV-8 DNA 
testing has been performed on plasma and peripheral blood mononuclear cells (174).  
However, performance characteristics of different nucleic acid amplification assays can be 
limited by inconsistent standardization and varied testing modalities and may not be directly 
comparable across laboratories(136)(130, 157, 164).  Though quantitative viral load is not a 
sensitive method to diagnose KS, MCD or PEL,  it may be used in conjunction with the 
clinical-pathologic presentation to support the diagnosis and management of these HHV-8 
related diseases (143, 175) (109, 165, 176-179). 
 
When PT-KS is diagnosed, further workup including imaging and invasive investigative 
procedures (e.g. bronchoscopy, esophagogastroduodenoscopy, colonoscopy) may be 
warranted for disease staging. Two staging strategies have been proposed(180, 181).  Non-
neoplastic clinical syndromes similarly rely on clinical-pathologic patterns including 
DNAemia and detection of virus in involved tissues, as well as the exclusion of other 
mimickers and co-infections.   
 
Treatment 
The initial approach to management of neoplastic and non-neoplastic HHV-8 associated 
disease relies on careful reduction or cessation of pharmacologic immunosuppression, though 
evidence to support efficacy in MCD or PEL is limited to case reports(114, 144, 165, 182-
184). Decreasing immunosuppression alone can result in complete remission in up to 30% of 
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patients with PT-KS(182).  Severity of disease, organ transplanted, and risk of rejection 
should be used to guide the extent to which immunosuppressive therapy is tapered.  When 
possible, immunosuppressive regimens containing calcineurin inhibitors (CNI) should be 
switched to mammalian target of rapamycin (mTOR) inhibitors such as sirolimus in the 
setting of HHV-8 related disease, particularly PT-KS.  Though KS regression has been 
routinely described with mTOR inhibitors, their use may also be associated with a decreased 
risk of post-transplant malignancy(185, 186).  In addition to their role in inhibiting T-cell 
proliferation in transplant recipients, mTOR inhibitors promote antiangiogenic effects by 
impairing the expression and function of vascular endothelial growth factor (VEGF) and 
interfere with virus-specific pathways needed for viral replication(139, 187-191).   
Interestingly, conversion of CNI to sirolimus has also been associated with simultaneous 
HHV-8 specific cytotoxic T-cell recovery(110, 114).  Though antiproliferative effects of 
mTOR inhibitors may be beneficial, cases of PT-KS while on sirolimus have been 
reported(192).  
 
Though ganciclovir, foscarnet, cidofovir, may exhibit antiviral activity in vitro, and 
successful use of these agents for HHV-8 related disease has been reported, no prospective, 
controlled trials have been performed to demonstrate efficacy in the post-transplant 
setting(155, 193-195).  Therefore, antivirals should not be routinely used for HHV-8 related 
disease. 
Oncology consultation should be pursued for patients with lesions that do not respond to 
immunosuppression reduction or conversion to sirolimus. Topical or intralesional 
chemotherapy, and radiation may be used, as well as cytotoxic chemotherapy for severe or 
visceral disease. Most commonly liposomal anthracyclines, doxorubicin or daunorubicin, are 
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used as first line systemic chemotherapeutic agents in AIDS-related KS.  Other agents such 
as paclitaxel, vincristine, vinblastine, bleomycin and etoposide have been used and promising 
studies evaluating pomalidomide, bevacizumab, sorafenib and imatinib are ongoing(196).  
Treatments for MCD and PEL are even more limited by the lack of robust, quality studies.  
Rituximab, an anti-CD20 agent, used for MCD treatment in non-transplant patients, has 
shown promise and may improve survival(197).  Given the rarity of PEL, limited treatment 
studies exist.  However, chemotherapy remains the first-line therapy as permitted by 
functional status and comorbid conditions(198). Case reports using antiviral medications 
(both systemic and intracavitary in PEL) coupled with immunosuppression reduction or CNI 
to mTOR inhibitor conversion have reported successful outcomes in MCD and PEL(165, 
167, 197).  Also, treatment of HHV-8 DNAemia and non-neoplastic manifestations using 
different antiviral agents as well as rituximab has been described and may be effective(109, 
157, 160).  
HHV-8 specific T-cell mediated immunity (CMI) monitoring in the setting of resultant 
neoplastic and non-neoplastic disease presentations may allow more precise and 
personalized immunosuppressive management and dynamics may correspond with disease 
progression or resolution(109, 113, 114).  Though data aiming to define the role of the 
HHV-8 CMI are promising, there is no compelling evidence at this time to support the use 
of adoptive immunotherapy for the treatment or prevention of HHV-8 related diseases.  
Recent studies have suggested a role for therapeutic autologous cytomegalovirus (CMV) 
specific T-cells for the treatment of resistant or refractory CMV infections, providing hope 
for similar precision therapy for viruses such as HHV-8(199).   
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Prevention 
Post-transplant HHV-8 viral load testing may be used as part of a disease monitoring and 
prevention strategy in seropositive recipients or seronegative recipients with seropositive 
donors in high seroprevalence areas (136, 141, 175).  However, a clinically relevant 
quantitative viral load “cut off”, optimal testing frequency and surveillance period duration 
post-transplant have not been defined. More frequent monitoring in mismatched recipients 
(D+/R-) in the first 3-6 months can be considered(136).  In HIV-infected patients ganciclovir 
and valganciclovir have been shown to inhibit HHV-8 replication and decrease KS 
incidence(193, 200).  However, using prophylactic or pre-emptive antivirals to prevent HHV-
8 related disease in SOT recipients has not been well studied.  Lowering immunosuppression 
in the setting of viral reactivations or primary infection is recommended to encourage 
recovery of HHV-8 specific T-cell immunity. Additionally, given mTOR inhibitors’ 
association with lower post-transplant malignancy, antiangiogenic effects, inhibition of viral 
replication, and HHV-8 specific cytotoxic T-cell recovery, conversion to sirolimus may be 
helpful in high risk patients with HHV-8 DNAemia, though no evidence of efficacy currently 
exists(114, 139, 187, 188).  Generally, monitoring of skin and mucosal surfaces through 
meticulous physical examination should also be routine in high risk patients. 
 
Research and future areas of investigation 
Further prospective trials are required to more carefully evaluate the specific role of HHV-8 
donor and recipient screening in endemic areas.  Additionally, determining the need for 
screening and defining such strategies outside of endemic regions will become more 
important as global population migration expands and HIV infected donors are recovered and 
recipients transplanted.  Similar evolution of the PHS increased risk donor landscape in the 
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United States and potential HHV-8 transmission risk remain to be explored. Optimal 
serologic screening relies on development of accurate, precise, and cost-effective tests.  
Though recent studies have demonstrated progress continued study is needed. In at-risk 
transplant recipients, strategic approaches to post-transplant viral load monitoring  including 
validation of clinically significant viral load thresholds, monitoring intervals and surveillance 
durations are needed to understand the role in preventing and predicting HHV-8 disease 
manifestations.  The utility of antiviral drugs and mTOR inhibitors for prevention and 
treatment HHV-8 after SOT needs prospective evaluation in large trials.  As our 
understanding of dynamic HHV-8 CMI develops, studies evaluating the function of immune-
monitoring strategies are necessary.  These studies should further investigate alteration of 
immunosuppression and influence of mTOR inhibitors on HHV-8 CMI and disease 
correlation. Similar to recent use for CMV therapy, the feasibility and safety of HHV-8 viral-
specific T-cells used for HHV-8 disease in SOT needs further study. 
 
HHV-8 recommendations and level of evidence 
 
 
Diagnosis 
Serology is of limited utility in the diagnosis of acute HHV-8 related disease post-transplant 
(strong, low). 
 
In endemic regions pre-transplant donor and recipient HHV-8 serologic screening may be 
helpful to stratify disease risk after transplant (weak, low). 
 
Targeted pre-transplant HHV-8 serologic screening of at-risk donors and recipients or those 
from endemic regions may be considered in low seroprevalence regions (weak, very low). 
 
Direct detection of HHV-8 from involved sites using immunohistochemical testing, in situ 
hybridization, or viral PCR is useful for diagnosis of HHV-8 related disease (strong, 
moderate). 
 
Quantitative PCR from clinical samples can detect active HHV-8 replication and may be 
useful for the diagnosis of HHV-8 related disease (strong, low). 
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Quantitative PCR can be used to monitor treatment response in post-transplant patients with 
HHV-8 related diseases (KS, MCD, PEL) (weak, very low). 
 
PT-KS disease staging including imaging and invasive investigative procedures (e.g. 
bronchoscopy, esophagogastroduodenoscopy, colonoscopy) should be considered (weak, 
low). 
 
Treatment 
Judicious reduction or cessation of immunosuppressive therapy should be first line therapy 
for patients with HHV-8 related disease (strong, low). 
 
Calcineurin inhibitor containing immunosuppressive regimens should be converted to mTOR 
inhibitors (mainly sirolimus) (strong, low). 
 
Antivirals should not be routinely used to treat HHV-8 related disease (weak, low). 
 
PT-KS unresponsive to reduction of immunosuppression or CNI to sirolimus conversion and 
severe or visceral disease may benefit from chemotherapy (strong, low). 
 
Prevention 
In HHV-8 seropositive recipients or those who receive an organ from a seropositive donor, 
viral load monitoring may be useful to predict clinical HHV-8 disease (weak, low). 
 
Reduction of immunosuppression in the setting of viral reactivations or primary infection and 
avoiding over immunosuppression in at risk recipients may be beneficial (weak, low).  
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